Comments
Loading...

SAB Biotherapeutics Analyst Ratings

SABSNASDAQ
Logo brought to you by Benzinga Data
$1.79
0.074.07%
At close: -
$1.67
-0.12-6.70%
After Hours: May 7, 8:32 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$20.00
Lowest Price Target1
$6.00
Consensus Price Target1
$11.40

SAB Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:SABS | Benzinga

SAB Biotherapeutics Inc has a consensus price target of $11.4 based on the ratings of 6 analysts. The high is $20 issued by Chardan Capital on April 1, 2025. The low is $6 issued by HC Wainwright & Co. on April 1, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and Chardan Capital on April 1, 2025, April 1, 2025, and January 29, 2025, respectively. With an average price target of $17 between Chardan Capital, HC Wainwright & Co., and Chardan Capital, there's an implied 849.72% upside for SAB Biotherapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
HC Wainwright & Co.
Craig-Hallum
Oppenheimer
Brookline Capital

1calculated from analyst ratings

Analyst Ratings for SAB Biotherapeutics

Buy NowGet Alert
04/01/2025Buy Now1017.32%Chardan Capital
Keay Nakae54%
$25 → $20MaintainsBuyGet Alert
04/01/2025Buy Now235.2%HC Wainwright & Co.
Edward White46%
$6 → $6ReiteratesBuy → BuyGet Alert
01/29/2025Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
01/29/2025Buy Now235.2%HC Wainwright & Co.
Edward White46%
$6 → $6ReiteratesBuy → BuyGet Alert
11/07/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
10/09/2024Buy Now514.53%Craig-Hallum
Albert Lowe26%
→ $11Initiates → BuyGet Alert
09/12/2024Buy Now570.39%Oppenheimer
Leland Gershell68%
$12 → $12ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
08/28/2024Buy Now570.39%Oppenheimer
Leland Gershell68%
→ $12Initiates → OutperformGet Alert
08/12/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
08/12/2024Buy Now235.2%HC Wainwright & Co.
Edward White46%
$6 → $6ReiteratesBuy → BuyGet Alert
06/07/2024Buy Now346.93%Brookline Capital
Kumaraguru Raja19%
→ $8Initiates → BuyGet Alert
05/21/2024Buy Now235.2%HC Wainwright & Co.
Edward White46%
$6 → $6ReiteratesBuy → BuyGet Alert
05/21/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
04/16/2024Buy Now235.2%HC Wainwright & Co.
Edward White46%
$6 → $6ReiteratesBuy → BuyGet Alert
04/16/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
04/02/2024Buy Now1296.65%Chardan Capital
Keay Nakae54%
$3 → $25MaintainsBuyGet Alert
04/02/2024Buy Now235.2%HC Wainwright & Co.
Edward White46%
$10 → $6MaintainsBuyGet Alert
01/08/2024Buy Now458.66%HC Wainwright & Co.
Edward White46%
$1 → $10ReiteratesBuy → BuyGet Alert
11/14/2023Buy Now-44.13%HC Wainwright & Co.
Edward White46%
$2 → $1MaintainsBuyGet Alert
10/05/2023Buy NowLadenburg Thalmann
Jeffrey Cohen29%
DowngradeBuy → NeutralGet Alert
08/21/2023Buy Now11.73%HC Wainwright & Co.
Edward White46%
$4 → $2MaintainsBuyGet Alert
06/21/2023Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4ReiteratesBuy → BuyGet Alert
06/16/2023Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4ReiteratesBuy → BuyGet Alert
06/15/2023Buy Now67.6%Chardan Capital
Keay Nakae54%
→ $3ReiteratesBuy → BuyGet Alert
05/17/2023Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4ReiteratesBuy → BuyGet Alert
04/27/2023Buy Now67.6%Chardan Capital
Keay Nakae54%
→ $3Reiterates → BuyGet Alert
04/13/2023Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4Reiterates → BuyGet Alert
04/03/2023Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4Reiterates → BuyGet Alert
11/29/2022Buy Now123.46%HC Wainwright & Co.
Edward White46%
→ $4Initiates → BuyGet Alert
08/11/2022Buy Now67.6%Chardan Capital
Keay Nakae54%
$7 → $3MaintainsBuyGet Alert
05/13/2022Buy Now291.06%Chardan Capital
Keay Nakae54%
$10 → $7MaintainsBuyGet Alert

FAQ

Q

What is the target price for SAB Biotherapeutics (SABS) stock?

A

The latest price target for SAB Biotherapeutics (NASDAQ:SABS) was reported by Chardan Capital on April 1, 2025. The analyst firm set a price target for $20.00 expecting SABS to rise to within 12 months (a possible 1097.60% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for SAB Biotherapeutics (SABS)?

A

The latest analyst rating for SAB Biotherapeutics (NASDAQ:SABS) was provided by Chardan Capital, and SAB Biotherapeutics maintained their buy rating.

Q

When was the last upgrade for SAB Biotherapeutics (SABS)?

A

There is no last upgrade for SAB Biotherapeutics

Q

When was the last downgrade for SAB Biotherapeutics (SABS)?

A

The last downgrade for SAB Biotherapeutics Inc happened on October 5, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for SAB Biotherapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.

Q

Is the Analyst Rating SAB Biotherapeutics (SABS) correct?

A

While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $25.00 to $20.00. The current price SAB Biotherapeutics (SABS) is trading at is $1.67, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch